Apogee Therapeutics (APGE) Net Income towards Common Stockholders (2022 - 2026)
Apogee Therapeutics (APGE) reported Net Income towards Common Stockholders of -$74.1 million for Q1 2026, down 33.92% year-over-year from -$112.2 million in Q1 2025, and down 6.81% quarter-over-quarter from -$69.4 million in Q4 2025.
Apogee Therapeutics (APGE) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has 5 years of Net Income towards Common Stockholders data on file, last reported at -$74.1 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$74.1 million, down 33.92% year-over-year; the trailing twelve-month figure through Mar 2026 was -$274.6 million (down 33.7% YoY), and the FY2025 annual result was -$255.8 million, down 40.46% from the prior year.
- Net Income towards Common Stockholders fell to -$74.1 million in Q1 2026 per APGE's latest filing, from -$69.4 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$1.8 million in Q2 2022 and troughed at -$74.1 million in Q1 2026.
- A 5-year average of -$39.5 million and a median of -$33.0 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders plunged 939.92% in 2023, then decreased 3.23% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$14.0 million in 2022, then sank by 126.57% to -$31.7 million in 2023, then slumped by 111.81% to -$67.2 million in 2024, then decreased by 3.23% to -$69.4 million in 2025, then fell by 6.81% to -$74.1 million in 2026.
- Business Quant data shows APGE's Net Income towards Common Stockholders at -$74.1 million in Q1 2026, -$69.4 million in Q4 2025, and -$65.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Apogee Therapeutics | 6.29 Bn | 5.23 Bn | - | -74.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74.11 Mn |
| Dec 31, 2025 | -69.39 Mn |
| Sep 30, 2025 | -65.02 Mn |
| Jun 30, 2025 | -66.10 Mn |
| Mar 31, 2025 | -55.34 Mn |
| Dec 31, 2024 | -67.22 Mn |
| Sep 30, 2024 | -49.02 Mn |
| Jun 30, 2024 | -33.82 Mn |
| Mar 31, 2024 | -32.09 Mn |
| Dec 31, 2023 | -31.74 Mn |
| Sep 30, 2023 | -20.84 Mn |
| Jun 30, 2023 | -18.89 Mn |
| Mar 31, 2023 | -12.53 Mn |
| Dec 31, 2022 | -14.01 Mn |
| Sep 30, 2022 | -19.66 Mn |
| Jun 30, 2022 | -1.82 Mn |